Skip to main content
    I

    Imunon Inc (IMNN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.59
    -0.04 (-5.56%)

    Market Cap: $4.08M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Imunon Inc (IMNN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Imunon reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$14.50M, operating cash flow was -$13.90M and free cash flow was -$14.18M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$3.75M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $14.65M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$500.00K0.0%100.0%-4984.3%-7179.6%
    Dec 2021$500.00K0.0%100.0%-4201.4%-4153.9%
    Dec 2020$500.00K0.0%100.0%-3697.3%-4296.7%
    Dec 2019$500.00K0.0%100.0%-4113.1%-3370.3%
    Dec 2018$500.00K0.0%100.0%-4213.0%-2376.7%
    Dec 2017$500.00K0.0%100.0%-3693.7%-4080.4%
    Dec 2016$500.00KN/A100.0%-4130.0%-4410.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$500.00K$500.00K$500.00K$500.00K$500.00K$500.00K$500.00K
    Gross profit$0$0$0$500.00K$500.00K$500.00K$500.00K$500.00K$500.00K$500.00K
    Research and development$7.78M$11.64M$11.29M$11.73M$10.62M$11.34M$13.07M$11.87M$13.08M$14.62M
    Operating income-$14.65M-$19.13M-$21.03M-$24.92M-$21.01M-$18.49M-$20.57M-$21.07M-$18.47M-$20.65M
    Net income-$14.50M-$18.62M-$19.51M-$35.90M-$20.77M-$21.48M-$16.85M-$11.88M-$20.40M-$22.05M
    EBITDA-$13.95M-$18.41M-$20.65MN/A-$20.42MN/A-$16.67MN/AN/A-$20.33M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0-$725.20K$0$0$0$727.16K$0$0$0$7.05M
    Gross profit$0$0$0-$169.26K$0$0$0-$165.29K$0$0$0$6.91M
    Operating income-$3.45M-$2.79M-$4.31M-$4.26M-$3.48M-$2.77M-$4.15M-$4.15M-$4.96M-$5.01M-$5.01M-$5.97M
    Net income-$3.75M-$2.81M-$4.25M-$4.22M-$3.43M-$2.74M-$4.10M-$4.06M-$4.85M-$4.79M-$4.93M-$4.89M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, the balance sheet showed $8.78M in cash and equivalents and no debt.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$12.29M$9.72M$21.92M$43.98M$74.05M$37.53M$38.28M$46.86M$47.51M$30.85M
    Current assets$10.72M$8.01M$18.24M$36.78M$51.95M$18.82M$16.24M$28.13M$24.31M$4.51M
    Cash and equivalents$8.78M$5.87M$5.84M$11.49M$19.59M$17.16M$6.88M$13.35M$11.44M$2.62M
    Total liabilities$5.23M$5.47M$8.53M$14.65M$18.25M$18.92M$23.72M$25.99M$20.81M$24.12M
    Short-term debt$0$452.36K$485.42K$1.42M$0$1.12M$1.84M$0N/A$2.56M
    Long-term debt$0N/AN/A$4.61M$5.85M$3.93M$7.96M$9.42M$0N/A
    Shareholder equity$7.06M$4.24M$13.39M$29.33M$55.80M$18.61M$14.56M$20.86M$26.70M$6.73M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$12.01M$14.99M$8.02M$12.29M$8.99M$8.79M$6.86M$9.72M$14.39M$9.69M$14.32M$21.92M
    Total liabilities$9.39M$10.80M$4.66M$5.23M$4.91M$6.13M$6.41M$5.47M$6.20M$5.95M$5.83M$8.53M
    Cash and equivalents$4.04M$6.86M$4.79M$8.78M$5.25M$4.73M$2.87M$5.87M$10.31M$5.31M$2.35M$5.84M
    Shareholder equity$2.62M$4.19M$3.36M$7.06M$4.08M$2.66M$452.03K$4.24M$8.19M$3.74M$8.50M$13.39M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$13.90M-$18.85M-$19.02M-$23.10M-$16.22M-$15.62M-$20.26M-$7.04M-$16.64M-$18.38M
    Capital expenditures$280.57K$29.54K$451.76K$267.80K$311.61K$19.09K$349.16K$138.40K$38.63K$62.50K
    Free cash flow-$14.18M-$18.88M-$19.47M-$23.36M-$16.54M-$15.64M-$20.61M-$7.18M-$16.68M-$18.44M
    Dividends paid$10.28K$0N/AN/AN/AN/AN/AN/AN/AN/A
    Share repurchases$10.28K$0N/AN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$280.57K$9.83M$11.01M$8.28M-$30.12M$7.92M$5.94M-$1.63M-$10.99M$9.06M
    Financing cash flow$17.09M$9.06M-$3.64M$6.72M$54.77M$17.98M$7.84M$10.58M$36.45M$2.68M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.20M-$3.03M-$3.99M-$3.66M-$4.44M-$2.95M-$2.85M-$4.42M-$4.06M-$4.50M-$5.87M-$3.77M
    Capital expenditures$1.79K$69.08K$0$3.59K$3$17.33K$259.65K$14.91K$2.88K$3$11.76K$5
    Free cash flow-$3.20M-$3.09M-$3.99M-$3.66M-$4.44M-$2.97M-$3.11M-$4.44M-$4.06M-$4.50M-$5.89M-$3.77M
    Last 12 quarters

    Frequently Asked Questions About IMNN

    What is Imunon's annual revenue?

    Imunon reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Imunon profitable?

    No. Imunon reported net income of -$14.50M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does IMNN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.90M minus capital expenditures of $280.57K produced free cash flow of -$14.18M.

    How much debt does Imunon have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $0 and cash and equivalents of $8.78M.